Loxo Oncology bought by Eli Lilly (2019)
Loxo, a precision-oncology firm, raised money from public investors to fund targeted cancer drugs. After its first drug won FDA approval, Eli Lilly bought the company for about $8 billion.
Loxo shareholders got a large premium, and Lilly absorbed the pipeline and approved drug.
The deal became a template for big pharma buying small precision-oncology firms once their lead drug clears regulatory risk.
It shows the path IDEAYA could follow: raise capital, win approval, then attract a buyer. Scenario 4 turns on this pattern.
